Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Analyst Ratings
Strong Buy
16 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
REGN Stock 12 Month Forecast
Average Price Target
$801.75
▲(43.55% Upside)
| Highest Price Target$979.00 | Average Price Target$801.75 | Lowest Price Target$535.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
Reiterated
05/05/25
Goldman Sachs
Reiterated
04/30/25
Truist Financial
Reiterated
04/30/25
Robert W. Baird
Reiterated
04/30/25
Roth MKM
Reiterated
04/30/25
Leerink Partners
Reiterated
04/29/25
Bank of America Securities
$547→$535
Sell
-4.21%
Downside
Reiterated
04/29/25
Regeneron's Eylea Challenges Prompt Underperform Rating Amid Market Erosion and FDA SetbackWe were not allowed to participate in Q&A unfortunately, for unspecified reasons. Our focus since re-instatement of coverage has focused on Eylea, the performance of which is the reason we believe shares are down - 8%; we have written about this matter extensively. This has been the basis of our Underperform rating. Besides weak Eylea sales in Q1, the company also made the surprising disclosure that FDA is not approving the "pre-filled syringe" formulation of Eylea HD at this time. See body of this report for our full paraphrasing on these and other topics.
Wells Fargo
$750→$700
Buy
25.33%
Upside
Reiterated
04/29/25
Regeneron (REGN) Gets a Buy from Wells Fargo
BMO Capital
$865
Buy
54.87%
Upside
Reiterated
04/29/25
Evan Seigerman's Buy Rating on Regeneron: Overcoming Challenges with a Promising Pipeline and Undervalued Assets
Cantor Fitzgerald
$695
Buy
24.44%
Upside
Reiterated
04/29/25
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Actinium Pharmaceuticals (NYSE MKT: ATNM) and Novo Nordisk (NYSE: NVO)
J.P. Morgan
$1,000→$950
Buy
70.09%
Upside
Reiterated
04/29/25
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD) and Regeneron (NASDAQ: REGN)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
Reiterated
05/05/25
Goldman Sachs
Reiterated
04/30/25
Truist Financial
Reiterated
04/30/25
Robert W. Baird
Reiterated
04/30/25
Roth MKM
Reiterated
04/30/25
Leerink Partners
Reiterated
04/29/25
Bank of America Securities
$547→$535
Sell
-4.21%
Downside
Reiterated
04/29/25
Regeneron's Eylea Challenges Prompt Underperform Rating Amid Market Erosion and FDA SetbackWe were not allowed to participate in Q&A unfortunately, for unspecified reasons. Our focus since re-instatement of coverage has focused on Eylea, the performance of which is the reason we believe shares are down - 8%; we have written about this matter extensively. This has been the basis of our Underperform rating. Besides weak Eylea sales in Q1, the company also made the surprising disclosure that FDA is not approving the "pre-filled syringe" formulation of Eylea HD at this time. See body of this report for our full paraphrasing on these and other topics.
Wells Fargo
$750→$700
Buy
25.33%
Upside
Reiterated
04/29/25
Regeneron (REGN) Gets a Buy from Wells Fargo
BMO Capital
$865
Buy
54.87%
Upside
Reiterated
04/29/25
Evan Seigerman's Buy Rating on Regeneron: Overcoming Challenges with a Promising Pipeline and Undervalued Assets
Cantor Fitzgerald
$695
Buy
24.44%
Upside
Reiterated
04/29/25
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Actinium Pharmaceuticals (NYSE MKT: ATNM) and Novo Nordisk (NYSE: NVO)
J.P. Morgan
$1,000→$950
Buy
70.09%
Upside
Reiterated
04/29/25
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD) and Regeneron (NASDAQ: REGN)
Best Analysts Covering Regeneron
Which Analyst Should I Follow If I Want to Buy REGN and Sell After:
1 Month
xxx
Success Rate
23/41 ratings generated profit
Average Return
+1.11%
assigned a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.10% of your transactions generating a profit, with an average return of +1.11% per trade.
3 Months
xxx
Success Rate
12/20 ratings generated profit
Average Return
+1.97%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +1.97% per trade.
1 Year
Success Rate
14/20 ratings generated profit
Average Return
+12.51%
reiterated a buy rating 9 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +12.51% per trade.
2 Years
xxx
Success Rate
14/20 ratings generated profit
Average Return
+13.98%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +13.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
REGN Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
17
21
17
22
18
Buy
21
17
19
22
16
Hold
11
9
8
7
5
Sell
3
3
2
5
4
Strong Sell
0
0
0
0
0
total
52
50
46
56
43
Each month's total comprises the sum of three months' worth of ratings.
REGN Financial Forecast
REGN Stock Forecast FAQ
What is REGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron’s 12-month average price target is 801.75.
What is REGN’s upside potential, based on the analysts’ average price target?
Regeneron has 43.55% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is REGN a Buy, Sell or Hold?
Regeneron has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 1 sell ratings.
What is Regeneron’s price target?
The average price target for Regeneron is 801.75. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $979.00 ,the lowest forecast is $535.00. The average price target represents 43.55% Increase from the current price of $558.52.
The highest analyst price target is $979.00 ,the lowest forecast is $535.00. The average price target represents 43.55% Increase from the current price of $558.52.
What do analysts say about Regeneron?
Regeneron’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of REGN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.